EIKEN CHEMICAL CO.,LTD.
4549・Prime Market・Pharmaceuticals
Business
Eiken Chemical was founded in 1939 and operates as a single-segment company whose sole business is the manufacture and sale of clinical diagnostic reagents. Its core product lineup consists of Fecal Occult Blood Test Reagents, Urinalysis Reagents, Immunoserological Diagnostic Reagents (including Fecal Occult Blood Test Reagents), and Microbiological Testing Reagents, with domestic hospitals, testing centers, and health screening institutions as its primary customers. Overseas sales reached ¥11,457 million (27.3% of net sales) in FY2026 (ending March 2026), driven by the growing adoption of fecal occult blood test reagents for colorectal cancer screening, mainly in Europe. The company also deploys LAMP-based tuberculosis and malaria genetic testing systems in developing countries such as those in Africa and India, contributing to the global health field. Its capital and business alliance with Otsuka Pharmaceutical (concluded in 2006), which supports collaboration in product development and sales, is also a key part of its competitiveness.
Business Model
The mainstay reagent products generate revenue based on ongoing consumable sales to medical institutions and testing centers, with a structure in which reagent demand arises steadily following instrument installation. Domestic sales are conducted through major pharmaceutical wholesalers such as Suzuken, Alfresa, and Toho Pharmaceutical, with each accounting for approximately 11% of sales. Overseas, the company utilizes its European branch in the Netherlands, a U.S. subsidiary, and a distributor network. In addition, LAMP method patent royalty income contributes to profit, and in FY2026 (ending March 2026), sales in the "Others" category (Others (Medical Devices, Genetic-related, etc.)) reached ¥7,305 million (up 15.2% year on year).
Company Strengths
Demand for fecal occult blood test reagents for overseas markets continues to expand, particularly in Europe, with overseas sales in FY2026 (ending March 2026) reaching ¥11,457 million (up 7.0% year on year). The company's own strength lies in the sales network and product track record it has built over many years to capture structural demand driven by the expansion of the age range eligible for colorectal cancer screening in various countries and the increasing number of newly adopting countries.
The Tuberculosis Testing System (TB-LAMP), based on proprietary LAMP-method nucleic acid amplification technology, has been adopted as a WHO-recommended test, and in December 2025 the Loopamp MTBC Detection Kit and two other products obtained WHO Prequalification certification. Continuous patent royalty income is also generated, and the technological entry barrier together with international credibility serve as differentiating factors versus competitors.
The equity ratio at the end of FY2026 (ending March 2026) remained at a high level of 70.1% (improved from 69.3% at the end of the previous fiscal year). Cash and cash equivalents stood at ¥7,943 million, and the company also holds overdraft and loan commitment agreements totaling ¥8,600 million, giving it the financial capacity to fund large-scale capital investments—such as the construction of the new Nogi production building (total investment of ¥6,666 million)—through a combination of retained earnings and borrowings.
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) reached ¥41,899 million (up 3.4% year on year), marking the first increase in two periods. This was driven by overseas sales of ¥11,457 million (up 7.0% year on year) and Others (Medical Devices, Genetic-related, etc.) of ¥7,305 million (up 15.2% year on year). Meanwhile, operating profit declined to ¥2,919 million (down 2.7% year on year), falling for the second consecutive period. The main cause was a rise in the cost of sales ratio, driven by fluctuations in overseas markets and changes in sales composition associated with the closure of USAID. Compared to FY2022 (ending March 2022), which saw special demand from COVID-19 (operating profit of ¥8,387 million), profit levels remain more than 65% lower, and this decline has continued. For FY2027 (ending March 2027), operating profit is expected to see a modest recovery to ¥3,070 million (up 5.2% year on year).
Growth Strategy
Overseas expansion of fecal occult blood test reagents, production efficiency improvements through consolidation at the Nogi plant, and focused efforts in the cancer and infectious disease fields form the three pillars of the strategy
The company continues to expand sales of overseas fecal occult blood test reagents against the backdrop of the spread of colorectal cancer screening in various countries. Overseas sales for FY2027 (ending March 2027) are projected at ¥11,790 million (up 2.9% year on year). However, geopolitical risks such as the closure of USAID exist as downside factors.
Following the transfer of equity in the Chinese subsidiary (Eiken Biotechnology (China) Co., Ltd.) in September 2025, consignment processing has been consolidated at the Nogi plant. In FY2026 (ending March 2026), ¥5,756 million was invested in the acquisition of property, plant and equipment, increasing the net amount of buildings and structures from ¥11,585 million to ¥17,484 million. Construction in progress decreased from ¥5,600 million to ¥767 million, entering the completion stage.
The company is promoting three areas as pillars of its medium-term management plan: "Contribution to cancer prevention and treatment" (Multi-Gene Mutation Detection System (MINtS), etc.), "Contribution to the eradication of infectious diseases and infection control" (Tuberculosis Testing System (TB-LAMP), etc.), and "Provision of products and services useful for healthcare" (remote health checkups and at-home testing). R&D expenses were ¥3,676 million (reduced from ¥4,386 million in the previous fiscal year).
The company is advancing efforts to improve profitability, targeting operating profit of ¥3,070 million (up 5.2% year on year) and ordinary profit of ¥2,900 million (up 2.0% year on year) for FY2027 (ending March 2027). The annual dividend is to be maintained at ¥58 (forecast for FY2027, ending March 2027), continuing the policy of a total return ratio of 50% or more. The dividend payout ratio for FY2026 (ending March 2026) is 51.5%.
Last updated: July 19, 2026